Esophageal String Test®, a Less Invasive Way to Monitor Adults and Children With Eosinophilic Esophagitis (EoE), Launches in the US

Esophageal String Test®, a Less Invasive Way to Monitor Adults and Children With Eosinophilic Esophagitis (EoE), Launches in the US

October 24, 2022 Eric Jones 0

Esophageal String Test®, a Less Invasive Way to Monitor Adults and Children With Eosinophilic Esophagitis (EoE), Launches in the USEsophageal String Test®, a Less Invasive Way to Monitor Adults and Children With Eosinophilic Esophagitis (EoE), Launches in the USTest offers EoE patients a simple, clinically proven method to control their disease. “…Beyond thrilled to use this at Phoenix Children’s Hospital…” – Dr. Schroeder, Medical Director, Eosinophilic Disease Clinic, Phoenix Children’s Hospital

AURORA, Colo. – October 24, 2022 – (Newswire.com)

Clinicians with the Gastrointestinal Eosinophilic Disease Program at the Digestive Health Institute, Children’s Hospital of Colorado, performed the Esophageal String Test® (EST) on a patient in early September. The test will be offered regularly at the hospital.

The EST was also performed on patients in the Eosinophilic Gastrointestinal Disease Clinic at Phoenix Children’s Hospital. 

I am now beyond thrilled to use this new esophageal surveillance technique at Phoenix Children’s and for my patients with eosinophilic gastrointestinal disorders. The EST is a game-changer for my patients who are looking for a less invasive and less expensive way to screen their disease activity,” said Dr. Shauna Schroeder, Medical Director for the Eosinophilic Gastrointestinal Disease Clinic at Phoenix Children’s Hospital. She further stated “Having trained in Denver, I had experience using the EST as a research tool in patients with eosinophilic esophagitis. I am now able to more granularly adjust medications and diets improving the care of my patients with eosinophilic esophagitis.”

The Esophageal String Test® utilizes a simple collection device, the EnteroTracker®, to collect upper gastrointestinal samples from adults and children.  The samples are sent to an independent reference lab for analysis of disease activity. Several other clinics around the country are planning to offer the test soon.

About EnteroTrack 

EnteroTrack, an early-stage company, develops simple-to-use, minimally invasive technologies to sample gastrointestinal (GI) mucosal content that can be assayed for various biomarkers of disease. The company’s platform technology, the EnteroTracker® is initially being used to support clinical monitoring of Eosinophilic Esophagitis in adults and children without need for sedation, advanced training, or complex procedures. Clinical studies evaluating the utility of the EnteroTracker® for additional applications including Esophageal Adenocarcinoma, Barrett’s Esophagus, GERD, GI microbiome, food allergy testing, and others are currently underway.

Contact Information:

Robin Shandas

CEO, Media and Investor Inquiries
[email protected]

Brookelynn Stillwell

General Inquiries
[email protected]

Press Release Service
by
Newswire.com

Original Source:

Esophageal String Test®, a Less Invasive Way to Monitor Adults and Children With Eosinophilic Esophagitis (EoE), Launches in the US

Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study

Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study

October 24, 2022 Editor 0

Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal StudyGb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal StudyGb Sciences’ anxiety formulations were previously identified using the company’s AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the National Research Council of Canada.

LAS VEGAS – October 24, 2022 – (Newswire.com)

Gb Sciences, Inc. (“GbS”; OTCQB:GBLX), a leading plant-inspired research and biopharmaceutical drug development company, has received positive preclinical results in an interim report from its study using preclinical zebrafish models of stress at the National Research Council of Canada (NRC). GbS’ proprietary anxiety formulations have achieved a statistically significant reduction of stress in this preclinical study. The NRC is testing GbS’ proprietary, psychotropic plant-based formulas for the treatment of depression and anxiety. GbS has leveraged its patent-pending PhAROS™ (Phytomedical Analytics for Research Optimization at Scale) platform to identify these combinations of plant compounds for novel drug candidates. These are the company’s first non-cannabis formulations to advance in preclinical studies.

“We have achieved an important milestone in the development of our novel, kava-inspired anxiety formulations. Not only did some of our formulations achieve statistical significance in the animal model, but these minimum essential mixtures also demonstrated synergy by significantly outperforming the individual active ingredients within our minimum essential mixture formulations,” said Dr. Andrea Small-Howard, Gb Sciences’ President and Chief Science Officer. “This preclinical data also confirms that our PhAROS™ platform was capable of yielding concrete, potentially effective, plant-inspired combination drugs.”

For these novel psychotropic drug candidates, the Gb Sciences research team used the PhAROS™ platform to identify new ingredients to improve upon an initial formulation for anxiety based on traditional medicine. The original plant mixture was derived from the kava plant, but some elements of kava are thought to cause liver toxicity. PhAROS™ identified ingredients from the Piper plant family as a substitute for the functionality of the ingredients in question without the potentially adverse safety profiles of those original ingredients. The Piper plant family includes pepper plants that are used worldwide in traditional medicines.

The PhAROSTM platform is a revolutionary, AI-driven science gateway and virtual research environment for drug discovery. With its data analytics and machine learning capabilities, PhAROS™ allows Gb Sciences to greatly reduce the time and money required to bring novel, plant-inspired formulations to market. PhAROS™ represents a breakthrough combination of data sciences and traditional plant-based medicines. 

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC). The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects,” “intends,” “plans,” “may,” “could,” “should,” “anticipates,” “likely,” “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Media Contact

Alexis Quintal

[email protected]

Contact Information:

Madeleine Moench

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study

Surgery Meets the Metaverse

Surgery Meets the Metaverse

October 21, 2022 Editor 0

Surgery Meets the MetaverseSurgery Meets the MetaverseDr. Robert Masson Performs the First Reconstructive Surgeries Using a Mixed Reality Operating Room Setup and Logistics Platform

Live Surgery Holo…

Mpowered Health Launches xChange, the Nation’s First Consumer Mediated Healthcare Data Exchange

Mpowered Health Launches xChange, the Nation’s First Consumer Mediated Healthcare Data Exchange

October 20, 2022 Editor 0

Mpowered Health Launches xChange, the Nation’s First Consumer Mediated Healthcare Data ExchangeMpowered Health Launches xChange, the Nation’s First Consumer Mediated Healthcare Data ExchangeThe healthcare exchange enables nearly 200 million people to share their medical records with caregivers, plans, providers and other organizations.

Mpowered Health Launches xChange, the Nation’s First Consumer Mediated Healthcare Data Exchange
Mpowered Health launches xChange

xChange is the Nation’s first consumer mediated health data exchange platform

LOS ALTOS, Calif. – October 20, 2022 – (Newswire.com)

Mpowered Health, a consumer healthcare marketplace, today announced that it successfully launched its xChange, the nation’s first consumer mediated healthcare data exchange. 

The exchange enables health plans, health systems and other healthcare organizations to request and obtain medical records from consumers with their consent. Consumers can now conveniently share records with family members and caregivers in addition to healthcare organizations they receive care from.

“There are over 100 million individuals in Medicare and Medicaid, who are vulnerable and in need of caregiver support. The xChange makes it easy for such consumers to share important information about their health with the people and the organizations that support them,” says Nandini Devi, Founder & CEO of Mpowered Health. “Consumers can control at a granular level who sees what information. This offering is the lynchpin of our vision to empower consumers to take control of their healthcare experience while enabling healthcare organizations to serve their consumers more effectively.”   

Consumers can connect to over 600 healthcare organizations such as health systems, medicare advantage & medicaid plans across the country including national payers, blues and regional plans. The Mpowered Health App enables nearly 200 million people across the country to access their medical records, coverage & explanation of benefits information from all these plans and health systems. In addition, the platform delivers a personalized shopping experience for consumers seeking to enroll in medicare and exchange health plans. Mpowered Health is the first healthcare platform in the United States to offer consumers such a convenience at scale.

Founded in 2019, Mpowered Health is a rapidly growing healthcare marketplace that provides a convenient platform for healthcare organizations to acquire, engage and retain consumers, while giving consumers a voice, the transparency, the choice, the access and the convenience they need to manage their own and their family’s health care.

Mpowered Health was featured in the Inc. Magazine and CIO Today in 2022 and as one of the Top Healthcare Interoperability Solution Providers by Healthcare TechOutlook.

About Mpowered Health

Mpowered Health is a consumer-driven healthcare technology company committed to creating a better healthcare experience for consumers and healthcare enterprises. The California-based company empowers consumers to take charge of their healthcare by providing mobile-led solutions that improve transparency, choice, access and convenience. The company, in recognizing that consumer empowerment cannot be a zero-sum game, provides enterprise solutions in compliance, consumer acquisition & engagement to enable healthcare organizations to serve their consumers more effectively and achieve their organizational goals.
 

For more information, visit us at www.mpoweredhealth.com

Media Contact: [email protected]

Contact Information:

Mpowered Health

Press

[email protected]

9740335480

Press Release Service
by
Newswire.com

Original Source:

Mpowered Health Launches xChange, the Nation’s First Consumer Mediated Healthcare Data Exchange